/PRNewswire/ The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Pulse Biosciences, Inc. (NASDAQ: PLSE) securities between January.
Earlier this week a class action complaint was filed against the defendants Pulse Biosciences, Inc.by the plaintiff Viron Bryan Ngosiok in the Northern
/PRNewswire/ The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Pulse Biosciences, Inc. (NASDAQ: PLSE) securities between January.
Pulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer - read this article along with other careers information, tips and advice on BioSpace
(2)
Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, today announced that the first CellFX
procedures in the European Union were successfully completed. The initial commercial use of the non-thermal, cellular-focused CellFX System to clear common benign lesions, now expands the Company s controlled launch program starting with the top aesthetic dermatologists and plastic surgeons across Europe. This strategic rollout in Europe will run in parallel with the Company s U.S. controlled launch aimed at building a strong foundation of clinical and commercial advocacy as the Company grows a promising global business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210219005136/en/